FDA delays decision on Regenxbio’s Hunter syndrome gene therapy by three months

It may take the FDA three months longer than expected to decide whether to approve Regenxbio’s gene therapy for a rare disease called Hunter syndrome, the company announced Monday evening. The agency pushed its decision ...